Printer Friendly

CORTECH MODIFIES BRADYCOR SIRS/SEPSIS STUDY TO INCLUDE A RISK MODEL BASED ON APACHE III DATABASE

 DENVER, June 29 /PRNewswire/ -- Cortech Inc. (NASDAQ: CRTQ) announced today that it is filing with the FDA a revised analysis plan for its Phase II study of Bradycor(TM) in patients with the systemic inflammatory response syndrome (SIRS) and suspected sepsis based on a risk model derived from the APACHE(TM) III Database, according to Timothy C. Rodell, M.D., senior vice president of Operations and Product Development.
 Bradycor is a drug that blocks the action of bradykinin, a peptide that is generated in response to injury and which is a pivotal mediator of pain, endothelial cell damage, hypotension (low blood pressure) and edema (fluid buildup in body tissues). It is currently being studied in a double-blind, placebo controlled study that will enroll 500 patients with SIRS and suspected sepsis. The risk model based on the APACHE III methodology will allow Cortech to measure the effect of Bradycor on patients according to their individual risk of mortality. This prospective analysis of risk potentially allows the company to define according to their risk profile patient subgroups that may demonstrate maximum benefit from Bradycor.
 The APACHE III Sepsis Risk Model is a unique and powerful method designed to measure baseline risk for each patient entered into the trial. The model is derived from the analysis of over 100,000 patients within the APACHE III International Database. The APACHE methodology has been developed over the past 15 years and is accepted throughout the world as the severity scoring system for critically ill patients.
 "The incorporation of the APACHE III Risk Model has the potential to increase the statistical power of the study significantly because it allows us to adjust for the severity of the patient's underlying illness at the time of study entry before assessing the effect of the drug," said Rodell. "This variability in the patient's risk of mortality can lead to variability in drug response. Without the power to detect and correct for variability in risk, a positive effect of the drug can be obscured. However, this analysis obviously cannot change whether or not the drug works and even if the results of this study are positive, we would still expect to perform an additional confirmatory study prior to NDA submission."
 "We are extremely pleased that Cortech has chosen to use the APACHE III Risk Model," said Gerald E. Bisbee, Jr., PhD, chairman and chief executive officer of APACHE Medical Systems Inc. "We believe APACHE III is the state-of-the-art analytical tool for evaluating the benefits of sophisticated drugs in complex diseases such as sepsis."
 Cortech is a Denver-based biopharmaceutical company that is developing a variety of therapies for inflammatory diseases, allergies and selected autoimmune diseases. No assurance can be given, however, that the company's therapeutic approaches will complete clinical trials or lead to successful product launches and product revenues. Shares of the publicly traded company are listed as CRTQ on NASDAQ.
 APACHE Medical Systems is the creator and developer of the APACHE III Critical Care Database. Two main product lines are derived from and contribute to the proprietary APACHE III Database: information systems for hospitals and physicians and clinical trial design and database management services for biological, pharmaceutical and other commercial companies.
 -0- 6/29/93
 /CONTACT: Timothy C. Rodell, M.D. of Cortech, 303-650-1200/
 (CRTQ)


CO: Cortech Inc.; APACHE Medical Systems Inc. ST: Colorado IN: MTC SU:

MC -- DV006 -- 6778 06/29/93 14:40 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:566
Previous Article:DICK LINDBERG JOINS AUTOWEEK ADVERTISING SALES STAFF
Next Article:MET-ED TO INSTALL FIRST SIEMENS MODEL V84.3 ADVANCED TECHNOLOGY GAS TURBINE-GENERATOR; COMPANIES COLLABORATE IN 'PARTNERS-IN-POWER' PROGRAM
Topics:


Related Articles
CORTECH STARTS PHASE II SIRS/SEPSIS STUDY
/C O R R E C T I O N -- CORTECH/
SYNERGEN'S PHASE III SEPSIS TRIAL SHOWS MORTALITY REDUCTION IN MOST SERIOUSLY ILL PATIENTS
CORTECH RELEASES THIRD QUARTER RESULTS
CORTECH 1993 HIGHLIGHTS
CORTECH CONTRACTS ABBOTT TO DEVELOP COMMERCIAL BRADYCOR MANUFACTURING PROCESS
CORTECH ANNOUNCES FILING FOR ADDITIONAL PHASE II SIRS/SEPSIS STUDY
CORTECH PRESENTS PHASE II SEPSIS TRIAL DATA
CORTECH ANNOUNCES RESULTS OF ADDITIONAL ANALYSES OF ITS FIRST SEPSIS TRIAL
CORTECH ANNOUNCES REDUCTION IN WORK FORCE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters